MetaVia Inc.
No SEC Form 4 filings for $MTVA in the last 30 days.
See all $MTVA insider activity →MetaVia Inc. (MTVA) appointed Sarah Browne as Chief Medical Officer, effective October 12, 2026. Browne has over 20 years of experience in clinical development and regulatory science. Her hire precedes the expected Q4 2026 topline results from Phase 1 Part 3 of DA-1726, a drug targeting cardiometabolic diseases and MASH.
MetaVia Inc. (MTVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fou
MetaVia Inc. (MTVA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001638287 0001638287 2026-06-08 2026-06-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MTVA (MetaVia Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent MTVA coverage spans financial news, earnings and corporate actions.
The new CMO brings extensive experience in cardiometabolic drug development, which could de‑risk the DA‑1726 program and support upcoming trial readouts.
DA-1726 dose-titration completion and upcoming 16-week topline are near-term execution milestones that can shift probability-weighted outcomes and funding expectations.
Dilution via equity plan share increase and potential liquidity/valuation reset from an approved reverse split are the key near-term trading overhangs.
AlphAI scores every news story that mentions MTVA with an AI model for sentiment and relevance, and aggregates insider trades from MetaVia Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MetaVia Inc. (MTVA) appointed Sarah Browne as Chief Medical Officer, effective October 12, 2026. Browne has over 20 years of experience in clinical development and regulatory science. Her hire precedes the expected Q4 2026 topline results from Phase 1 Part 3 of DA-1726, a drug targeting cardiometabolic diseases and MASH.
1 min readMetaVia Inc. (MTVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726 16-Week Topline Data Expected in the Fou
4 min readMetaVia Inc. (MTVA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001638287 0001638287 2026-06-08 2026-06-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min read
